Navigation Links
Sugammadex Study First to Show Rapid Reversal of Profound Rocuronium-Induced Muscle Relaxation is Possible
Date:10/28/2008

nd uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 8.01 of the company's 8-K filed Oct. 21, 2008.

Endnote

(1) Jones RK, Caldwell JE, Brull SJ, Soto RG Reversal of Profound Rocuronium-induced Blockade with Sugammadex: A Randomized Comparison with Neostigmine. Anesthesiology. 2008;109(5):816-824.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. New Study Highlights Need for Better Interaction and Education Between Rheumatoid Arthritis Patients and Care Providers
2. QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System
3. Psychological study reveals that red enhances mens attraction to women
4. Study reveals factors of exceptional health in old age
5. Eating whole grains lowers heart failure risk, according to new study
6. Bloomberg School of Public Health to lead nationwide aging study
7. Latest Pistachio Study Reveals Significant Reduction in Markers of Inflammation - an Emerging Risk Factor in Heart Disease
8. University of Illinois - Chicago Study: Raisins Contain Compounds that May Inhibit Cavity-causing Bacteria
9. Study Reveals Factors of Exceptional Health in Old Age
10. AUDIO from Medialink and Genzyme: Study in New England Journal of Medicine Shows Investigational Compound Reduced Relapses and Disability in Patients With MS
11. Study finds that practice makes perfect in lung cancer surgery
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Barr Confirms Patent Challenge of Xyzal(R), 5mg Tablets 2Health News:Barr Confirms Patent Challenge of Xyzal(R), 5mg Tablets 3Health News:Pill Could Boost Sports Performance 2Health News:Get Straight A's in Snacking with Supercharged Superfruits from Fruitaceuticals! 2Health News:'Who's Who' Weight Specialist Martin Schiff, M.D., 86, Devoting Rest of Life to Spreading Truth About Diets, Won't Accept Compensation From Anyone, Sending Complete Guide Free to All 2Health News:Liver damage in hepatitis C patients could be treated with warfarin, says study 2Health News:Liver damage in hepatitis C patients could be treated with warfarin, says study 3Health News: Freescale and Monebo Launch ECG-on-a-Chip Platform Solution to Aid Heart Monitoring : Advanced Hardware and Software Technology Designed to Enable More Efficient and Higher Quality Cardiac Care 2
Breaking Medicine Technology:Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Autism Support Network Launches Enhanced Features Adds Thousands of New Members Globally 57318 1Autism Support Network Launches Enhanced Features Adds Thousands of New Members Globally 57318 2Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 1Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 2Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 3Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 4Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz Lamivudine and Tenofovir Disoproxil Fumarate Tablets 57314 1Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz Lamivudine and Tenofovir Disoproxil Fumarate Tablets 57314 2
Other Medicine Technology:Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 2Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 3Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 4Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 5Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 6Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 2Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 3Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 4Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 5